Kashfi Simon, Nasser Mohamed Farhan, Soleiman Aron, Sharma Sapna, Koripalli Venkata Sandeep, Sharma Shorabh
CUNY School of Medicine, New York, NY, USA.
Heart and Vascular Center, MetroHealth Medical Center/Case Western Reserve University, Cleveland, OH, USA.
Eur J Case Rep Intern Med. 2022 May 5;9(5):003355. doi: 10.12890/2022_003355. eCollection 2022.
Clot in transit (CIT) is a rare condition in which a venous thromboembolism becomes lodged in the right heart. It is seen in up to 18% of patients with massive pulmonary embolism, and if left untreated, mortality rates are between 80% and 100%. The identification and management of CIT are crucial. However, there are no current guidelines for the treatment of CIT. We present the case of a 44-year-old woman who was found to have CIT that was ultimately treated with medical management.
Clot in transit (CIT) is a dangerous entity that must be promptly managed.Risk factors for CIT include a history of heart failure, a pre-existing central venous catheter and recent hospitalization.New interventions are emerging for the treatment of CIT.
移行性血栓（CIT）是一种罕见的病症，即静脉血栓栓塞栓子滞留于右心。在高达18%的大面积肺栓塞患者中可见，若不治疗，死亡率在80%至100%之间。CIT的识别与处理至关重要。然而，目前尚无治疗CIT的指南。我们报告一例44岁女性患者，其被诊断为CIT，最终接受了药物治疗。
移行性血栓（CIT）是一种必须迅速处理的危险病症。CIT的危险因素包括心力衰竭病史、既往存在中心静脉导管以及近期住院。针对CIT的治疗正在出现新的干预措施。
